Search clinical trials for: CS1-CAR T Therapy

Total 2479 results

The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University

Recruiting

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Immunotherapy

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Carbiogene Therapeutics Co. Ltd.
Zhejiang Provincial People's Hospital

Recruiting

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

AML M5 | AML M4

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

CD7+ Acute Leukemia | CD7+ Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-Cell

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Hepatocellular Carcinoma

China
University of Colorado, Denver

Active, not recruiting

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Non Hodgkin Lymphoma

United States
Guangzhou Bio-gene Technology Co., Ltd

Withdrawn

Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Completed

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Relapse | Lymphomas Non-Hodgkin's B-Cell

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

CAR-T Cell Immunotherapy | EphA2 Positive Malignant Glioma

China
Zhi Yang

Withdrawn

A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer

Glioma | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
First Affiliated Hospital of Chengdu Medical College

Unknown

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (CARTEPC)

Gastric Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Esophageal Carcinoma | Hepatic Carcinoma

China
Xuzhou Medical University

Unknown

Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy

Hematopoietic/Lymphoid Cancer

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Malignant Tumor

China
Sinobioway Cell Therapy Co., Ltd.
Jiangsu Cancer Institute & Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (EECPL)

Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Nanjing IASO Biotechnology Co., Ltd.
Ruijin Hospital

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
The University of Hong Kong
Chinese University of Hong Kong; Hong Kong Alzheimer's Disease Association

Completed

A Culturally Appropriate Multimodal Non-pharmacological Intervention for Chinese People With Mild-to-Moderate Dementia

Dementia

Hong Kong
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO)

Non-Hodgkin's Lymphoma | B-Cell ALL | B-Cell CLL

United States
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Antonio Pérez Martínez

Recruiting

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma (CAR4SAR)

Advanced Sarcoma

Spain
Shanghai Cell Therapy Group Co.,Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Simnova Biotechnology Co.,Ltd.
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of RD14-01 in Patients With Advanced Solid Tumors

Solid Tumor

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Crystal Mackall, MD

Recruiting

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

Brain and Nervous System

United States
Suzhou Immunofoco Biotechnology Co., Ltd
Changhai Hospital

Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Gastric Cancer | Pancreatic Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Ovarian Carcinoma

China
Shanghai Mengchao Cancer Hospital
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Solid Tumor

China
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (CAR-T)

Refractory Leukemia | Relapse Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Peking University

Unknown

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Lymphoma

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Not yet recruiting

A Clinical Study of CD19 CAR-T in Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Shanghai East Hospital
Bio4T2 LLC

Recruiting

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors

Advanced Solid Tumor

China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Multiple Myeloma in Relapse

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Systemic Scleroderma | Dermatomyositis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | SLE (Systemic Lupus)

China
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China

Search clinical trials for: CS1-CAR T Therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations